|
Urology News and Education Resource
 |
Saturday, 04 January 2025 |
|
|
|
|
|
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy
Misha Beltran, MD
Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute; providing funding to focus on the therapeutic side of who are the patients most likely to benefit from PSMA scanning.
|
|
|
|
|
|
|
Disruptive Technologies in Radiology & Nuclear Medicine Interview
Phillip J. Koo, MD, FACS
Phillip Koo and Alicia Morgans discuss disruptive changes impacting healthcare practices and new data challenging radiology and nuclear medicine today.
|
|
|
|
|
|
|
Theranostic Approaches for Advanced Prostate Cancer
Michael Hofman, MBBS (Hons), FRACP, FAANMS
Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia and highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and the utilization for fluorodeoxyglucose (FDG)-positron emission tomography (PET) vs PSMA PET.
|
|
|
|
|
|
|
A Review of Imaging Modalities in Prostate Cancer
Peter A. Pinto, MD
Peter Pinto highlights the paradigm shift of the use of new imaging technology for a more accurate diagnosis of prostate cancer in an interview with John Fortin. They discuss targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, metabolic and focal imaging.
|
|
|
|
|
|
|
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer
Felix Y. Feng MD
Felix Feng talks with Alicia Morgans on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up front.
|
|
|
|
|
|
|
18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer
Ur Metser, MD, FRCPC
Ur Metser presents a study conducted to determine if integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging.
|
|
|
|
|
|
|
|
|
|
|
